As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
13 Analysts have issued a Fulcrum Therapeutics Inc forecast:
13 Analysts have issued a Fulcrum Therapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -60 -60 |
124%
124%
|
|
| EBIT (Operating Income) EBIT | -61 -61 |
115%
115%
|
|
| Net Profit | -53 -53 |
198%
198%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Alexander Sapir |
| Employees | 45 |
| Founded | 2015 |
| Website | www.fulcrumtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


